Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Resected Breast Cancer Clear all
Completed No phase listed Observational

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

NCT00043472
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years to 100 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 5:32 PM EDT
Completed No phase listed Observational

Atypical Lesions of the Breast: Close Observation Versus Excision (ALCOVE)

NCT01925586
View directory record Official record
Conditions
Atypical Ductal Hyperplasia (ADH) of the Breast
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
40 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

NCT00769379
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation
Other · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
2,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1249
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 764 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 22, 2026, 5:32 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

NCT01259284
View directory record Official record
Conditions
Advanced Cancers
Interventions
Atorvastatin, Fish Oil Supplement, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Jul 22, 2026, 5:32 PM EDT
Not listed Not applicable Interventional

Intraoperative Use of ClearEdge Device in Breast Conserving Surgery

NCT05456373
View directory record Official record
Conditions
Breast Cancer
Interventions
ClearEdge device
Device
Lead sponsor
LS BioPath
Industry
Eligibility
18 Years and older · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Investigation of Novel Surgical Imaging for Tumor Excision

NCT03686215
View directory record Official record
Conditions
Breast Cancer
Interventions
Study Device Arm
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Mobile, Alabama • Scottsdale, Arizona • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Jul 22, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891
View directory record Official record
Conditions
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Ribociclib, Fulvestrant, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Oana Danciu
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Long Term Use of SAVI SCOUT: Pilot Study

NCT03015649
View directory record Official record
Conditions
Breast Diseases
Interventions
SAVI SCOUT Surgical Guidance System
Device
Lead sponsor
Envision Healthcare Scientific Intelligence, Inc.
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Early Phase 1 Interventional

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer

NCT03411070
View directory record Official record
Conditions
Positive Axillary Lymph Node, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Implanted Medical Device, Therapeutic Conventional Surgery
Device · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Selective Image Guided Resection of Axillary Lymph Nodes

NCT01880645
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine Needle Aspiration (FNA), Ultrasound, Breast Surgery + Lymph Node Removal
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Jul 22, 2026, 5:32 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Real-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM Diagnostics

NCT04683120
View directory record Official record
Conditions
Oncology, Breast Cancer, Cancer Diagnosis, Margins of Excision, Margins, Tumor-Free
Interventions
Zenith FLIM Diagnostics
Diagnostic Test
Lead sponsor
Laser LabCorp
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Post Market Study Using the Xoft Axxent System

NCT01017549
View directory record Official record
Conditions
Breast Cancer
Interventions
Electronic brachytherapy (Axxent System)
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
10
States / cities
San Mateo, California • Marietta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Phase 1Phase 2 Interventional

Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant

NCT00977275
View directory record Official record
Conditions
Breast Cancer
Interventions
Interstitial Implant Brachytherapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Jul 22, 2026, 5:32 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

NCT05892068
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Tucatinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

NCT00016432
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane, Placebo
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
150
States / cities
Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Jul 22, 2026, 5:32 PM EDT
Recruiting Not applicable Interventional

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

NCT06903468
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Breast Cancer
Interventions
Novel cavity marking technique
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Drain Placement for Seroma Prevention After Mammosite/SAVI Catheter Removal

NCT02390661
View directory record Official record
Conditions
Infected Seroma After Surgical Procedure
Interventions
Penrose drain placement
Device
Lead sponsor
Michigan State University
Other
Eligibility
45 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Phase 1 Interventional

Study of ST266 Versus Saline in Treating Skin Irritation From Radiation

NCT01714973
View directory record Official record
Conditions
Radiation-induced Dermatitis
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Early Phase 1 Interventional

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

NCT01467310
View directory record Official record
Conditions
Breast Cancer
Interventions
GSK1120212
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer

NCT01271738
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of Breast, Cancer of the Breast, Human Mammary Carcinoma, Neoplasms, Breast
Interventions
Remove tumor only, Removal of tumor and tissue
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast

NCT00165256
View directory record Official record
Conditions
Ductal Carcinoma in Situ of the Breast
Interventions
Observation
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

NCT00305695
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Zoledronic Acid
Other · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
95
States / cities
Scottsdale, Arizona • Tucson, Arizona • Burbank, California + 76 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Jul 22, 2026, 5:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
88
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional

Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ

NCT00002934
View directory record Official record
Conditions
Breast Cancer
Interventions
long-term screening
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
29
States / cities
Atlanta, Georgia • Decatur, Georgia • Evanston, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 22, 2026, 5:32 PM EDT